{"id":1005694,"date":"2026-09-24T10:10:07","date_gmt":"2026-09-24T14:10:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/"},"modified":"2026-09-24T10:10:07","modified_gmt":"2026-09-24T14:10:07","slug":"autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/","title":{"rendered":"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company&#8217;s international patent portfolio<\/i>\n      <\/p>\n<p align=\"justify\">\n        <b>THE WOODLANDS, TX, Sept.  24, 2026  (GLOBE NEWSWIRE) &#8212; <\/b><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4kB7VYZARi8LPHZ23cuxfYeUKrqoOb9tz0zniBiww4a_bBpx7rbLSbHY4zVw5bgXAJJ-QSe3ici0q3O_3Cwz0-W6_7tnjeDG_DKcSQqAYlFefiitMLN0AUBQJ8uGpVmvWZSGdSb0VekI-t-7CM0gyUfcJk4bHV-5t2cKNrkXf6-NeFEaESt59FLbe-A8cz3yjd9D1z6hP27wbFKmo3tqsHfo9hgWBGVjKnNfXweTO7tbV1hVVKQ-_eTzdWxpiWUVMHR4Tiq3ix2eLoYFZ1nMaQ==\" rel=\"nofollow\" target=\"_blank\">Autonomix Medical, Inc.<\/a>\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled &#8220;<i>Systems for Assessing Neural Activity in an Eye<\/i>.&#8221; The newly issued patent further expands the Company&#8217;s international intellectual property portfolio and strengthens protection for technologies supporting autonomic nervous system assessment and precision neuromodulation across Europe.<\/p>\n<p align=\"justify\">The European patent covers technologies designed to assess autonomic nervous system activity through the monitoring and analysis of neural activity within the eye. The patent includes systems and methods for evaluating physiologic responses through ocular measurements that may support patient assessment, treatment guidance and procedural feedback across a variety of autonomic nervous system disorders and neuromodulation applications.<\/p>\n<p align=\"justify\">&#8220;This European patent represents another important step in expanding our global intellectual property footprint,&#8221; said Brad Hauser, Chief Executive Officer of Autonomix. &#8220;As we continue advancing our precision nerve-targeted technology platform, building a broad international patent portfolio remains a key strategic priority. This patent enhances protection for technologies supporting autonomic nervous system assessment and complements our growing portfolio covering precision nerve sensing, mapping and targeted neuromodulation.&#8221;<\/p>\n<p align=\"justify\">The granted patent complements Autonomix&#8217;s expanding portfolio of issued and pending patents protecting technologies spanning autonomic nervous system assessment, neural sensing, treatment guidance and transvascular neuromodulation. Together, the Company&#8217;s growing international patent estate supports its strategy of developing differentiated technologies designed to precisely identify, assess and target disease-associated nerves across multiple therapeutic applications.<\/p>\n<p align=\"justify\">Autonomix continues to advance its proprietary technology platform designed to detect and differentiate neural signals with significantly greater sensitivity than conventional technologies, supporting the development of precision nerve-targeted therapies intended to improve patient outcomes while minimizing unintended effects on surrounding tissue.<\/p>\n<p align=\"justify\">\n        <b>About Autonomix Medical, Inc.\u00a0<\/b>\n      <\/p>\n<p align=\"justify\">Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company\u2019s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever,\u00a0transvascular\u00a0diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.\u00a0<\/p>\n<p align=\"justify\">We are initially developing this technology for the treatment of pain, with\u00a0initial\u00a0trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology\u00a0constitutes\u00a0a platform to address dozens of potential indications, including cardiology,\u00a0hypertension\u00a0and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.\u00a0<br \/>\u00a0<br \/>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Arpz6cwAeW86IfGZ96k0R8XKWOPs1vWF9qMcH02ZaWsjjoxu2k0oG3cJpglF9NuMTmeTARDrTmo1YoDrl3di2A==\" rel=\"nofollow\" target=\"_blank\">autonomix.com<\/a>\u00a0and connect with the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XT0H5TIGXO0HHzYqe6iElVfA-xedm7TC6SgRee_Po_3Sv0CXoZoK62QUnqzKwAtneY6VlZJ37CmE_5LAevKAZA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PkeiyC0aiUD662D3vpiXtrq7FGzGkHPox6gQdcZnCo37YFwNGBuJCOhVQw7kjagBkq_Xlt4rCvOMXbweLWr7rA5zuForfXRY9RQgDd3H4lagC5qnk6cn1wNxiaUOlORc\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oaU74ZGbVpCIRXttvGpBcTlmX_QRMGSa7xAkWeMh6rbUFsw-OMBAZeMG-4JNPcZ_d90fVwpbb17FGR5c-xsfQ2Em_Rz25876Q8z0QAVSr10=\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=44rF2En4puDJKvH7EaqgqvKvBx39kEshCH_plZtCzMV-0x_W93ISxBPeAEygJE5K2RLJLpf8is84fSrtRXpsX1T12Qyx2L7k6DlCG-qCTv7vysHs6FXE02J1rS_uzqXg\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements\u00a0<\/b>\n      <\/p>\n<p align=\"justify\">Some of the statements in this release are \u201cforward-looking statements,\u201d which involve risks and uncertainties. Such forward-looking statements can be identified\u00a0by the use of\u00a0words such as \u201cshould,\u201d \u201cmight,\u201d \u201cmay,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201cexpects,\u201d \u201cplans,\u201d and \u201cproposes.\u201d\u00a0Forward-looking statements in this press release include, but are not limited to, expectations\u00a0regarding\u00a0the potential effectiveness and clinical benefits of\u00a0Autonomix&#8217;s\u00a0nerve-targeted treatments for pancreatic cancer pain and other conditions, the versatility and scalability of the Company&#8217;s platform technology, the potential for future clinical applications across multiple organ systems, the strength and scope of the Company&#8217;s intellectual property portfolio, and the potential for the Company&#8217;s patented technologies to support patient selection, procedural guidance and post-treatment monitoring across multiple neuromodulation applications.\u00a0<br \/>\u00a0<br \/>Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are\u00a0a number of\u00a0risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading \u201cRisk Factors\u201d and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of\u00a0this press release\u00a0and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.\u00a0<\/p>\n<p align=\"justify\">\n        <b>Investor and Media Contact\u00a0<\/b>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC<br \/>Jenene Thomas<br \/>908.824.0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Arpz6cwAeW86IfGZ96k0R-FP9rf_G5djTGTChIoFEBroXZg_56fczW3ToYWZ1TfAKwwlNUOuOnU-d0R-OFxHMzVjlBR9ALIeLg8Z12O2KyU=\" rel=\"nofollow\" target=\"_blank\">autonomix@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjhmNjcwZWItY2Q2MC00NDQzLThkNWQtMGNmYWEwOWU1MTlmLTUwMDExOTk5Mi0yMDI2LTA5LTI0LWVu\/tiny\/Autonomix-Medical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company&#8217;s international patent portfolio THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) &#8212; Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled &#8220;Systems for Assessing Neural Activity in an Eye.&#8221; The newly issued patent further expands the Company&#8217;s international intellectual property portfolio and strengthens protection for technologies supporting autonomic nervous system assessment and precision neuromodulation across Europe. The European patent covers technologies designed to assess autonomic nervous system activity through the monitoring and analysis of neural activity within the eye. The patent includes systems and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1005694","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company&#8217;s international patent portfolio THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) &#8212; Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled &#8220;Systems for Assessing Neural Activity in an Eye.&#8221; The newly issued patent further expands the Company&#8217;s international intellectual property portfolio and strengthens protection for technologies supporting autonomic nervous system assessment and precision neuromodulation across Europe. The European patent covers technologies designed to assess autonomic nervous system activity through the monitoring and analysis of neural activity within the eye. The patent includes systems and &hellip; Continue reading &quot;Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-24T14:10:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform\",\"datePublished\":\"2026-09-24T14:10:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/\"},\"wordCount\":758,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/\",\"name\":\"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==\",\"datePublished\":\"2026-09-24T14:10:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/","og_locale":"en_US","og_type":"article","og_title":"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform - Market Newsdesk","og_description":"European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company&#8217;s international patent portfolio THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) &#8212; Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled &#8220;Systems for Assessing Neural Activity in an Eye.&#8221; The newly issued patent further expands the Company&#8217;s international intellectual property portfolio and strengthens protection for technologies supporting autonomic nervous system assessment and precision neuromodulation across Europe. The European patent covers technologies designed to assess autonomic nervous system activity through the monitoring and analysis of neural activity within the eye. The patent includes systems and &hellip; Continue reading \"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-24T14:10:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform","datePublished":"2026-09-24T14:10:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/"},"wordCount":758,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/","name":"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==","datePublished":"2026-09-24T14:10:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMzMyMyM3ODYxODg2IzUwMDExOTk5Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-expands-global-intellectual-property-footprint-with-european-patent-supporting-precision-neuromodulation-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1005694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1005694"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1005694\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1005694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1005694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1005694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}